Novartis raises full-year core operating income guidance
NVS•Novartis raised its full-year core operating income growth forecast to a low single-digit percentage, from a previously expected low single-digit decline, while maintaining its forecast for low single-digit net sales growth.
1. Higher income outlook
Novartis raised its full-year core operating income guidance after strong third-quarter demand for its key cancer and multiple sclerosis drugs. The Swiss drugmaker now expects core operating income to grow by a low single-digit percentage, compared with its previous forecast for a low single-digit decline. It maintained its forecast for low single-digit net sales growth.
